Allogene Therapeutics, Inc. (ALLO)
$
1.17
-0.01 (-0.85%)
Key metrics
Financial statements
Free cash flow per share
-0.9199
Market cap
255.9 Million
Price to sales ratio
-11.6 Thousand
Debt to equity
0.2109
Current ratio
9.7121
Income quality
0.7821
Average inventory
0
ROE
-0.5650
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company that focuses on the development and commercialization of genetically engineered allogeneic T cell therapies to combat cancer. The company reported depreciation and amortization expenses of $13,639,000.00 reflecting the wear and tear of its assets, which is a vital element in assessing its financial health. The weighted average number of shares outstanding is 194,811,756.00 highlighting the company's shareholder base and its appeal to investors. Allogene’s operating expenses amount to $273,221,000.00 encompassing various operational costs incurred during its innovative development processes. The cost of revenue for the company is $0.00 showcasing its production and operational expenses, which are crucial to its overall profitability. Consequently, the gross profit stands at $22,000.00 highlighting the company's financial performance from core operations as it champions the fight against cancer. The company develops, manufactures, and commercializes products like UCART19 for R/R CD19 positive B-cell ALL, and several other promising candidates for various cancers, thus forming a diverse product portfolio that underscores its dedication to improving patient outcomes. The stock is affordable at $1.18 suitable for budget-conscious investors, making it accessible to a wider range of potential shareholders. Additionally, the stock has a high average trading volume of 3,372,912.00 indicating strong liquidity, which is often a desirable trait for active traders. With a market capitalization of $255,915,270.00 the company is classified as a small-cap player, positioning it uniquely within the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth, which enhances its reputation and attractiveness as an investment option. Through strategic collaborations and groundbreaking research, Allogene Therapeutics, Inc. continues to be a forward-thinking entity in the competitive field of immuno-oncology.
Is Allogene Therapeutics, Inc. (ALLO) a good investment?
Investing in Allogene Therapeutics, Inc. (ALLO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Allogene Therapeutics, Inc. (ALLO)'s stock forecast?
Analysts predict Allogene Therapeutics, Inc. stock to fluctuate between $0.86 (low) and $3.78 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Allogene Therapeutics, Inc.'s market capitalization?
As of 2025-05-30, Allogene Therapeutics, Inc.'s market cap is $255,915,270, based on 218,731,000 outstanding shares.
How does Allogene Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Allogene Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Allogene Therapeutics, Inc. (ALLO) stock?
To buy Allogene Therapeutics, Inc. (ALLO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALLO. Place an order (Market, Limit, etc.).
What is the best time to invest in Allogene Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Allogene Therapeutics, Inc. perform in the last earnings report?
Revenue: $22,000 | EPS: -$1.32 | Growth: -36.84%.
Where can I find Allogene Therapeutics, Inc.'s investor relations reports?
Visit https://www.allogene.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Allogene Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Allogene Therapeutics, Inc. stock?
All-time high: $39.12 (2021-03-16) | All-time low: $0.86 (2025-05-14).
What are the key trends affecting Allogene Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Allogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, especially for ALLO-316 in solid tumors, could be a major catalyst and validate Allogene's platform for broader indications. Despite immense upside potential, significant risks remain: safety, execution, regulatory uncertainty, and likely dilution due to future fundraising needs.
seekingalpha.com
Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data readouts. The company's financial position remains stable, supported by a strong cash runway and prudent expense management. Key strengths include a differentiated allogeneic CAR-T platform and strategic partnerships, though clinical and regulatory risks remain significant.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois.
zacks.com
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
seekingalpha.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Biren Amin - Piper Sandler Brian Chang - JPMorgan Matthew Biegler - Oppenheimer Samantha Semenkow - Citi John Newman - Canaccord Genuity William Pickering - Bernstein Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter and 2025 Conference Call.
globenewswire.com
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m.
zacks.com
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
seekingalpha.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Tyler Van Buren - TD Cowen Michael Yee - Jefferies Brian Cheng - JPMorgan Sami Corwin - William Blair Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Asthika Goonewardene - Truist Matthew Biegler - Oppenheimer Shelby Tucker - RBC Capital Markets Samantha Semenkow - Citi Carolina Ibanez-Ventoso - Stifel Laura Prendergast - Raymond James Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2024 Conference Call.
See all news
